Changeflow GovPing Pharma & Drug Safety CD80 Extracellular Domain Fc Fusion Proteins fo...
Routine Notice Added Final

CD80 Extracellular Domain Fc Fusion Proteins for Treating PD-L1 Negative Tumors

Favicon for changeflow.com ChangeBridge: Patent Grants - Peptides (C07K)
Published March 31st, 2026
Detected March 31st, 2026
Email

Summary

The USPTO granted Patent US12589132B2 to Five Prime Therapeutics, Inc. covering fusion proteins combining the CD80 extracellular domain with the Fc domain of IgG1 for treating PD-L1 negative tumors. The patent includes 22 claims and names Susannah D. Barbee, Thomas Brennan, and Barbara Sennino as inventors. This grant establishes exclusive rights for the assignee in this therapeutic application.

What changed

USPTO granted Patent US12589132B2 to Five Prime Therapeutics, Inc. for methods of treating PD-L1 negative tumors using fusion proteins comprising the extracellular domain of human CD80 and the Fc domain of human IgG1. The patent (application no. 17432640, filed 2020-02-21) contains 22 claims and is classified under CPC codes including A61K 38/1774 and C07K 14/70532.

No compliance action is required from pharmaceutical or healthcare entities. Companies developing similar CD80-Fc fusion therapeutics for PD-L1 negative tumors should review this patent to assess potential freedom-to-operate implications and consider licensing discussions with Five Prime Therapeutics if applicable.

Source document (simplified)

← USPTO Patent Grants

CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors

Grant US12589132B2 Kind: B2 Mar 31, 2026

Assignee

FIVE PRIME THERAPEUTICS, INC.

Inventors

Susannah D. Barbee, Thomas Brennan, Barbara Sennino

Abstract

The present disclosure provides methods of treating PD-L1 negative tumors, the methods comprising administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1).

CPC Classifications

A61K 38/1774 A61K 38/177 A61K 38/00 A61P 35/00 G01N 33/57492 G01N 2333/70532 G01N 2800/52 C12Q 2600/106 C12Q 2600/158 C12Q 1/6886 C07K 14/70532 C07K 2319/30

Filing Date

2020-02-21

Application No.

17432640

Claims

22

View original document →

Named provisions

CD80 Extracellular Domain Fc Fusion Proteins Methods of Treating PD-L1 Negative Tumors

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
USPTO
Published
March 31st, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US12589132B2

Who this affects

Applies to
Pharmaceutical companies Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent Grant
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: Patent Grants - Peptides (C07K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.